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Abstract 
PAX2 is the second member of the nine-member 
PAX gene family. PAX2's role begins as a 
developmental gene in late primitive streak stage 
embryos (Dressler et al., 1990). If PAX2 becomes 
expressed out of its normal context, its powerful 
functions as a transcription factor and epigenetic 
regulator (reviewed in Robson et al., 2006) can be 
recruited to the advantage of cancer cells (Robson et 
al., 2006; Li and Eccles, 2012). Normally PAX2 has 
key roles during embryogenesis, particularly in 
epithelial cell differentiation from mesenchyme 
(Rothenpieler and Dressler, 1993), such as in kidney 
development, and in mammary gland ductal 
morphogenesis (Silberstein et al., 2002). There is a 
requirement for the attenuation of PAX2 expression 
during development, particularly for the terminal 
differentiation of nephrogenic precursors (Dressler 
et al., 1993). Following the completion of 
development, PAX2 is capable of being re-
expressed, such as in instances of nephrotoxicity or 
in other kidney damage (Cohen et al., 2007). In adult 
tissues, PAX2 is normally expressed in the pancreas 
(Zaiko et al., 2004), and also in subpopulations of 
nodal lymphocytes (Gilmore and Dewar, 2011). 
When expressed out of its normal context, 
expression of PAX2 is frequently observed in 
several cancer types (Robson et al., 2006). 
Expression of PAX2 has been linked with cell 
survival (Torban et al., 2000; Muratovska et al., 
2003), cell migration and invasion (Buttiglieri et al., 
2004), and mesenchyme-epithelial transition (MET) 
and epithelial-mesenchyme transition (EMT) 
(Doberstein et al., 2011). 
Identity 
Other names: PAPRS 
HGNC (Hugo): PAX2 
Location: 10q24.31 




12 exons, including alternative spliced exons 6 and 
10 (Sanyanusin et al., 1996). 
Transcription 
Several alternatively spliced isoforms of PAX2 have 
been described involving exon 6, exon 10 (Dressler 
et al., 1990; Ward et al., 1994), and intron 9 (Busse 
et al., 2009). 
Pseudogene 
No 










PAX2 contains a DNA binding paired domain, a 
truncated homeodomain, an octapeptide region and 
a carboxyl-terminal transactivation domain 
(Sanyanusin et al., 1996).  
Degradation/destruction of the PAX2 protein in cells 
is mediated by the prolyl hydroxylase domain 
protein 3 (PHD3) protein (Yan et al., 2011).  
PHD3 is also known to hydroxylate hypoxia 
inducible factors (HIFα) in the presence of oxygen, 
and leads to HIFα proteosomal degradation.  
In some colorectal cancer cell lines where PAX2 
protein is expressed PAX2 expression was found to 
be elevated due to decreased PHD3 expression (Yan 
et al., 2011). 
Description 
416 amino acids; 44.7 kDa. 
Expression 
PAX2 is expressed in the developing eye, ear, central 
nervous system (CNS), spinal cord, pancreas and 




PAX2 is a transcription factor that regulates the 
expression of genes involved in mediating cell 
proliferation and growth, resistance to apoptosis, and 
cell migration (Dahl et al., 1997).  
PAX2 null mutant mice die perinatally with absent 
cochlea, kidneys, ureters, oviducts, vas deferens and 
epididymis, and also demonstrate mid- and 
hindbrain deficiency and defective optic nerves 
(Torres et al., 1995; Torres et al., 1996).  
PAX2's role in normal tissues includes promoting 
osmotic tolerance in the adult kidney (Cai et al., 
2005), determining axon number and axon trajectory 
in the developing optic nerve (Torres et al., 1996; 
Alur et al., 2008), and determining nephron number 
in the kidney (Dziarmaga et al., 2003; Dziarmaga et 
al., 2006; Clark et al., 2004).  
In cancer cells and in tumour endothelial cells the 
over-expression of PAX2 has been linked to the 
acquisition of a pro-invasive phenotype (Fonsato et 
al., 2008), and PAX2 has been suggested as a 
molecular target in tumour endothelial cells against 
which to design anti-angiogenic strategies (Bussolati 
et al., 2010). 
Homology 
PAX2 shares homology through the conserved 
paired box domain with several other members of the 
nine member PAX gene family (Dahl et al., 1997; 
Robson et al., 2006). 
Mutations 
Germinal 
PAX2 mutations have been reported as associated 
with renal coloboma syndrome (see below), 
oligomeganephronia and isolated renal hypoplasia 
(Bower et al., 2012; Bower et al., 2011). These 
mutations are collated on the Leiden Open Variant 
Database platform (www.lovd.nl/PAX2). A PAX2 
mutational hotspot and germline mosaiscism for 





PAX2 is activated by oestrogen and tamoxifen in 
endometrial carcinomas, but not in the normal 
endometrium, and this activation is associated with 
cancer-linked hypomethylation of the PAX2 
promoter (Wu et al., 2005; reviewed in Shang, 
2006).  
In the progression from normal to endometrial 
precancer to cancer, the expression of both PAX2 
and PTEN is progressively lost (Monte et al., 2010; 
Allison et al., 2012).  
Nevertheless, inhibition of PAX2 or silencing of 
PAX2 by RNAi inhibits the growth of transplanted 
human endometrial cancer cells in nude mice (Zhang 
et al., 2011). 
Breast cancer 
Note 
PAX2 is expressed in breast cancer cell lines and 
tissues (Silberstein et al., 2002). A role for PAX2 in 
the crosstalk between estrogen receptor (ER) and 
ERBB2/HER-2 pathways is suggested by the 
observation that PAX2 is an important mediator of 
ER-associated repression of ERBB2 following 
tamoxifen treatment (Hurtado et al., 2008). PAX2 
and the ER co-activator AIB-1/SRC-3 were found to 
compete for binding and regulation of ERBB2 
transcription. Competition for binding, and 
dependence of the effect of tamoxifen on PAX2 is 
responsible for tamoxifen-responsiveness in breast 
cancer cells, and might suggest potential 
mechanisms for tamoxifen-resistance in breast 
cancer. PAX2 expression is negatively correlated 
with the recurrence of breast cancer (Liu et al., 
2009), and expression of PAX2 is selectively 
achieved in breast cancer cells of the luminal subtype 
via ERα (Beauchemin et al., 2011).  
PAX2 has a role in maintaining a low invasive  
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behavior in luminal breast cancer cells upon 
exposure to estradiol. However, in contrast to PAX2, 
GPR30 expression is correlated with ER expression 
and showed significant association with ERBB2 
expression and also association with a tendency for 
tumour recurrence (Liu et al., 2009).  
An MCF-7 cell line that was selected for tamoxifen 
resistance resulted in several outgrowing sublines 
that acquired PAX2 expression, accompanied by 
loss of phosphorylated ERBB2, and rapamycin 
resistance (Leung et al., 2010). 
Ovarian carcinoma 
Note 
PAX2 is expressed in carcinomas of the ovary 
(Schaner et al., 2003; Muratovska et al., 2003; Tong 
et al., 2007). As compared with high-grade serous 
ovarian carcinomas, low-grade serous carcinomas 
are characterized by a greater expression of PAX2 
(Tung et al., 2009; Roh et al., 2010; reviewed in 
Gershenson, 2013). PAX2 expression was reduced 
in secretory cell outgrowths (SCOUTS), which are 
associated with serous ovarian cancer (Chen EY et 
al., 2010), and PAX2 expression has also been 
associated with SCOUTS and serous borderline 
tumours occurring in the fallopian tube (Laury et al., 
2011). A relationship between discrete PAX2 gene 
dysregulation in the oviduct and both increasing age 
and, more significantly, the presence of co-existing 
serous cancer has been suggested (Quick et al., 
2012). PAX2 appears to have both oncogenic and 
tumour suppressor gene roles in ovarian cancer cells, 
depending on the cellular context (Song et al., 2013). 
In chemoresistant epithelial ovarian cancer cell lines 
PAX2 expression was down regulated (Ju et al., 
2009). In ovarian cancer cell lines inhibition of 
PAX2 led to reduced cell proliferation and apoptosis. 
Renal cell carcinoma 
Note 
Renal cell carcinomas (RCC) cells express PAX2 
(Gnarra and Dressler, 1995; Daniel et al., 2001; 
Igarashi et al., 2001) as a result of loss of the von-
Hippel Lindau (VHL) tumour suppressor gene and 
hypoxia (Luu et al., 2009; reviewed in Kuroda et al., 
2013). PAX2 promotes cell survival in renal cell 
carcinoma cells (Hueber et al., 2006). PAX2 
expression correlates with proliferation index in the 
majority of kidney tumour subtypes, and expression 
levels are significantly higher as compared to 
primary RCCs in patients presenting with metastatic 
disease (Pan et al., 2013). PAX2 may therefore 
provide a useful prognostic marker for determining 
the severity of kidney cancers (Kuroda et al., 2013). 
PAX2 has been shown to regulate ADAM10, which 
is a metalloproteinase expressed in RCC cells. PAX2 
has been validated in vivo as a therapeutic target for 
the treatment of renal cell carcinoma cells (Hueber 
et al., 2008). Immunogenic HLA-A*0201-binding 
T-cell epitopes of PAX2 have been identified, which 
were able to generate a T-cell response to at least 1 
of 6 PAX2 peptide pools in patients with renal cell 
carcinoma, colorectal cancer, or lymphoma 
(Asemissen et al., 2009). 
Prostate cancer 
Note 
PAX2 is expressed in prostate cancer cell lines and 
in some prostate cancer tissues (Khoubehi et al., 
2001; Quick et al., 2010). During embryonic 
development in mice Pax2 mRNA levels are higher 
in the early stages of development than in 
postpubertal prostates (Chen Q et al., 2010). PAX2 
may regulate the early, androgen-independent stages 
of prostate development, and expression is 
associated with a dorsally localized epithelial cell 
population retaining proliferative and differentiation 
potential, which may represent a subset of stem-like 
cells with characteristics of castrate-resistant 
prostate cancer cells (Chen Q et al., 2010). 
Angiotensin II up-regulates the expression of PAX2 
in prostate cancer cells via the angiotensin II type I 
receptor (Bose et al., 2009b). Inhibition of PAX2 
expression leads to cell death in prostate cancer cells, 
independently of p53 (Gibson et al., 2007). In 
addition, PAX2 expression represses the expression 
of human beta defensin-1 (hBD1) in prostate cancer 
cells, which may be a mechanism by which PAX2 
helps to facilitate evasion of cancer cells from the 
immune system (Bose et al., 2009a). Human beta 
defensin is a component of the immune system 
linking innate and adaptive immune responses. 
Furthermore, PAX2 over-expression promotes the 
development of a metastatic state in prostate cancer 
cells, presumably through upregulating the 




Nephrogenic adenoma is a benign lesion of the 
urinary tract, particularly of the urinary bladder. 
Immunostaining for PAX2 and PAX8 is useful in the 
detection of nephrogenic adenomas and particularly 
unveils those nephrogenic adenomas that have a flat 
pattern (Piña-Oviedo et al., 2013). PAX2 is 
expressed in bladder cancer cells, and inhibition of 
PAX2 expression in bladder cancer cell lines induces 
cell death, indicating a role for PAX2 in tumour cell 
survival (Muratovska et al., 2003). 
Wilms tumor 
Note 
PAX2, as well as its closely related family member, 
PAX8, is expressed in Wilms tumor (Dressler and 
Douglass, 1992; Eccles et al., 1992), but neither 
PAX2 nor PAX8 is mutated in Wilms tumor 
(Tamimi et al., 2006). The gene encoding the 
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calcineurin a-binding protein (CnABP) was 
identified as a novel target gene, which is up 
regulated by PAX2 (Nguyen et al., 2009), and is 
over-expressed in >70% of Wilms tumor samples 
analysed. CnABP was shown to promote cell 
proliferation and migration in cell culture 
experiments (Nguyen et al., 2009). 
Melanoma 
Note 
PAX2 protein was expressed weakly in 
keratinocytes and melanocytes (Lee et al., 2011). 
Increased levels of PAX2 protein, as compared to 
melanocytes, were observed in some melanoma cell 
lines, and in some melanoma tissues, which strongly 
correlated with nuclear atypia and prominent 
nucleoli (i.e a more atypical cellular phenotype). 
PAX2 was found to regulate ADAM10 expression, 
which is a metalloproteinase with an important role 
in melanoma, and the silencing of PAX2 expression 
in melanoma cells abrogated chemoresistance, and 
anchorage-independent growth as well as decreasing 
migratory and invasive capacity of melanoma cells 
(Lee et al., 2011). 
Medulloblastoma 
Note 
PAX2 is expressed in the majority of 
medulloblastomas, and its expression correlates with 
a less differentiated histology. Inhibition of PAX2 
expression leads to apoptosis of medulloblastoma 
cells (Burger et al., 2012). 
Colorectal cancer 
Note 
In colorectal cancers PAX2 protein is elevated due 
to decreased PHD3 expression (Yan et al., 2011). 
Silencing of PAX2 in colorectal cancer cells inhibits 
the activity of AP-1, a transcription factor that 
induces cyclin D1 expression (Zhang et al., 2012). 
PAX2 protein expression in colorectal cancer cells 
prevents JUNB from binding to c-jun and enhances 
phosphorylation of c-Jun (Zhang et al., 2012). 
Kaposi's sarcoma 
Note 
PAX2 is expressed in Kaposi's sarcomas (Buttiglieri 
et al., 2004), where it induces apoptosis resistance 
and a proinvasive phenotype. 
Renal coloboma syndrome (RCS) 
Note 
RCS is associated with heterozygous PAX2 
mutations (Sanyanusin et al., 1995). RCS is  
characterised by end-stage renal failure and 
blindness (Eccles and Schimmenti, 1999; Bower et 
al., 2011). Increased apoptosis arises as a result of 
impaired PAX2 function, and is believed to be 
responsible for disrupted nephron formation 
(Porteous et al., 2000). Optic nerve defects are also 
observed in patients with RCS, and these lead to 
visual impairment (Eccles and Schimmenti, 1999). 
There are no reported instances of cancer in patients 
with renal-coloboma syndrome. 
Polycystic kidney disease 
Note 
An aberrant persistent expression of PAX2 is 
implicated in autosomal dominant polycystic kidney 
disease, and cystogenesis is inhibited when Pax2 
gene dosage is reduced in mice with ADPKD 
(Stayner et al., 2006; Eccles and Stayner, 2014). 
Similarly, in Cpk mice with recessive polycystic 
kidney disease, reduced dosage of the Pax2 gene was 
able to reduce cystogenesis, and also enhances 
apoptosis in fetal kidney cells (Ostrom et al., 2000). 
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